Artivion, Inc. Common Stock (AORT)

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Artivion (NYSE:AORT) and its ...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

What a brutal six months it’s been for Artivion. The stock has dropped 29.1% and now trades at $25.57, rattling many shareholders. This may have investors wo...

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...

What Happened? Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on ...

Revenue grew 9% as heart valve and stent graft products drove results.

Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve po...

Artivion (NYSE:AORT) reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined rou

Medical device company Artivion (NYSE:AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 ...

Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 mil...

Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after the bell. Here’s what to expect. Artivion met analysts’ revenue ex...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Artivion’s stock price has taken a beating over the past six months, shedding 43.8% of its value and falling to $24.10 per share. This was partly due to its ...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Artivion (NYSE:AORT) and its ...

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...